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Uveal melanoma (UM) is the most common primary adult intraocular malignancy.
This rare but devastating cancer causes vision loss and confers a poor survival rate
due to distant metastases. Identifying clinical and molecular features that portend a
metastatic risk is an important part of UM workup and prognostication. Current UM
prognostication tools are based on determining the tumor size, gene expression profile,
and chromosomal rearrangements. Although we can predict the risk of metastasis fairly
accurately, we cannot obtain preclinical evidence of metastasis or identify biomarkers
that might form the basis of targeted therapy. These gaps in UM research might be
addressed by single-cell research. Indeed, single-cell technologies are being increasingly
used to identify circulating tumor cells and profile transcriptomic signatures in single,
drug-resistant tumor cells. Such advances have led to the identification of suitable
biomarkers for targeted treatment. Here, we review the approaches used in cutaneous
melanomas and other cancers to isolate single cells and profile them at the transcriptomic
and/or genomic level. We discuss how these approaches might enhance our current
approach to UM management and review the emerging data from single-cell analyses
in UM.
Keywords: uveal melanoma, single-cell analysis, DEPArray NxT technology, CellSearch, circulating tumor cells,
FFPE, melanoma prognostication, melanoma surveillance
INTRODUCTION
Uveal melanoma (UM) is the most common primary adult intraocular malignancy (Carvajal et al.,
2017; Dogrusoz et al., 2017; Kaliki and Shields, 2017). Although rarely compared with other
cancers, UM is a devastating disease that causes both vision loss and confers a high death rate
due to metastasis that affects up to 50% of patients with primary UM (Kujala et al., 2003; Finger
et al., 2005). UM metastases occur most frequently in the liver and have a poor prognosis due
to limited treatment options (Eskelin et al., 2000; Buder et al., 2013; Shields and Shields, 2015).
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UM with a high risk of metastasis is associated with losses to
chromosomes 1p, 3, 6q, 8p, a gain of 8q (Damato et al., 2007,
2011; Harbour et al., 2010; Martin et al., 2013; Field et al., 2018)
and a Class 2 gene expression profile (Class 2 GEP) (Harbour and
Chen, 2013; Harbour, 2014). Several somatic mutations in UM
with prognostic significance have also been identified, including
mutations in BAP1, SF3B1, EIF1AX, and SRSF2 (Harbour et al.,
2010; Martin et al., 2013; Robertson et al., 2017; Field et al.,
2018). Consequently, and with the advent of new diagnostic
technologies, bespoke panels for UM harnessing next-generation
sequencing (NGS) to analyze both copy number variations
(CNVs) and the mutational status of the genes mentioned earlier
have been developed for prognostication purposes (Robertson
et al., 2017; Smit et al., 2018; Thornton et al., 2020). In addition,
clinicopathological features of UM—including the site and size
of the primary tumor, the presence of epithelioid cells, the
mitotic count, and the presence of connective tissue loops
(Force, 2015)—form part of the TNMClassification of Malignant
Tumors used for UM staging by oncologists to predict survival.
Prognostic testing for improving metastasis surveillance and
predicting survival is a concept that was first introduced by the
Liverpool Ocular Oncology Centre, which continues to provide a
UM surveillance service nationally and internationally (Damato
et al., 2007, 2011). The Liverpool Ocular Oncology Centre
has combined these parameters mentioned earlier to produce
a robust prognostic algorithm that can create individualized
prognostic curves for UM patients, stratifying them into groups
according tometastatic risk to facilitate surveillancemanagement
(Damato et al., 2011; Cunha Rola et al., 2020).
Unfortunately, the prognostic tools currently available only
allow us to identify high-risk patients requiring increased
surveillance. Current therapies for metastatic UM (mUM) are
still lacking and represent a notable gap in UM management.
Emerging evidence suggests that analyses of circulating tumor
cells (CTCs) and circulating free DNA (Anand et al., 2019)
might improve mUM surveillance, particularly in high-risk
UM patients. Indeed, single-cell analyses of the tumor cell
microenvironment and CTCs have already provided new insights
into UM tumor biology (Torres et al., 2011; Durante et al., 2020;
Karlsson et al., 2020). Herein, we provide an overview of the
current single-cell approaches that have transformed the field of
oncology, focusing on their application in cutaneous and UMs.
We also discuss novel single-cell approaches using formalin-fixed




Continual advancements in single-cell technologies have meant
that their application to and utility for cancer monitoring is
rapidly evolving (Navin, 2015). Technologies facilitating high-
throughput single- and rare-cell isolation platforms (Wang and
Navin, 2015; Valihrach et al., 2018) and single-cell NGS of
DNA, RNA, proteins, and metabolites (Wang and Navin, 2015;
Wills and Mead, 2015; Gawad et al., 2016; Suva and Tirosh,
2019; Lim et al., 2020) have greatly contributed to the field of
oncological theragnostics.
Single-Cell Isolation Techniques
Single-cell isolation can be used to select a homogenous tumor
cell population from the surrounding, infiltrating immune cells,
normal cells, or a rare cell population that comprises <1% of the
total cell population (Wang and Navin, 2015; Wills and Mead,
2015; Gawad et al., 2016; Valihrach et al., 2018; Suva and Tirosh,
2019; Lim et al., 2020). Although flow cytometry, microfluidics
platforms, and manual micromanipulation techniques can be
used to isolate an abundant tumor-cell population, detecting,
and isolating rare cancer cells are much more challenging
(Wang and Navin, 2015; Valihrach et al., 2018). However,
numerous methods and platforms for single-cell isolation are
currently available (Table 1). Single-cell isolation techniques
are particularly useful for detecting CTCs. Furthermore,
interest in CTCs has been increasing, as liquid biopsies
(such as blood samples) are readily accessible, and a high
CTC count in such samples seems to correlate with an
increased risk of metastasis in breast and other cancers
(Paget, 1989; Alix-Panabières and Pantel, 2016).
A major challenge in detecting CTCs lies in their rarity
in blood. As such, enrichment protocols such as ficoll
density gradient separation, red blood cell lysis (erythrolysis)
isolation, and immunomagnetic selection systems by Dynabeads
or Miltenyi CD45 beads (Kallergi et al., 2016) have been
developed and can be combined with the other single-cell
isolation techniques to aid detection. Some of these single-
cell isolation platforms (such as CellSearch and Magsweeper)
are specific for CTC identification, as they have incorporated
cytokeratin markers within their systems (Table 1) to improve
CTC detection. To date, CellSearch is the only Food and
Drug Administration-approved system for clinical use in breast,
colorectal, and prostate CTC detection (Millner et al., 2013;
De Luca et al., 2016; Kondo et al., 2017; Paolillo et al.,
2017).
Single-Cell Transcriptomics and Genomics
Single-cell transcriptomics and genomics can be used to
interrogate the profile of isolated single cells of interest. Single-
cell transcriptomics or single-cell RNA sequencing (scRNA-seq)
(Wang and Navin, 2015; Wills and Mead, 2015; Gawad et al.,
2016; Suva and Tirosh, 2019; Lim et al., 2020) provides a high-
resolution transcriptomic profile of every single cell that can be
used to understand the cellular function of each cell and how it
interacts with other cells (Wills and Mead, 2015; Gawad et al.,
2016; Suva and Tirosh, 2019). Such data have been used to define
the tumormicroenvironment (TME) and determine the profile of
tumor-infiltrating immune cells that may confer tumor survival
in breast and pancreatic carcinomas (McGranahan and Swanton,
2015; Chung et al., 2017; Davis et al., 2017; Bernard et al., 2019),
thus advancing our knowledge on how such cancers behave and
develop resistance.
Whole-genome amplification provides sufficient material
from a single cell for single-cell genomic analysis by single-cell
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TABLE 1 | Methods and platforms for single-cell isolation.
Technology Platforms/methods Principle of cell detection Main downstream
applications
Traditional Methods Laser-capture microdissection Manual dissection using a laser and under microscopic
visualization; requires tissue sections to be mounted on
specialized slides
• Isolation of rare cells and
population collection
• Cell-to-cell
interaction analysisNanofilters Select and sort single cells by size difference
Commercial Platforms (low
throughput, <100 cells)
CellRaft AIR System (CellMicrosystems) Automated platform with an integrated fluorescent
microscope to image, sort, and isolate cell
• Isolation of rare single cell
• scRNA-Seq
• scDNA-Seq
• Cell phenotypes analysis
• Cell clonality analysis
AVISO CellCelector (ALS) Fully automated image-based cell sorter that uses a robotic
capillary micromanipulator to isolate cells
DEPArray NxT (Menarini Silicon
Biosystems)
Fully automated, image-based, digital cell-isolation machine
that uses antibodies and microchip technology to capture
cells in dielectrophoretic cages
Puncher Platform (Vycap) Automated image-based system that uses silicon chips with
microwells and punching technology to isolate single cells
Commercial Platforms (medium
throughput, 100–1,000 cells)
ICELL8 Single-Cell System (Takara) Open-platform, automated system with a built-in imaging
station and software analysis tool; cells are isolated in
barcoded nanowells; RNAseq reagents can be dispensed
from coded chips
• scRNA-Seq
C1 System and Polaris (Fluidigm) Automated microfluidic system where cell capture, lysis,
reverse transcription, and cell multiplexing occur in an




throughput, more than 10,000
cells)
Chromium System (10x Genomics)
Automated, high throughput systems that use
droplet-based microfluidics for integrated cell isolation and
downstream analysis
• scRNA-Seq
• scDNA-SeqNadia (Dolomite Bio)
InDrop System (1CellBio)
ddSEQ Single-Cell Isolator (Illumina
Bio-Rad)
Tapestri Platform (MissionBio)
BD Rhapsody Single-Cell Analysis
System (BD)
Automated targeted transcriptomic approach using







Uses ferrofluid nanoparticles with EpCAM antibodies that




Magsweeper (Illumina Inc.) An immunomagnetic cell separator that captures single cells
with rotating magnetic rods
DNA sequencing (scDNA-seq) and array-based CNV analysis
(Knouse et al., 2017; Lawson et al., 2018; Tan et al., 2019). Such
approaches have been used to determine the mutational profile
of resistant subclones in acute lymphoblastic leukemia, as well as
colon and breast carcinomas to improve prognostication (Gawad
et al., 2014; Yu et al., 2014).
SINGLE-CELL APPROACHES IN
CUTANEOUS MELANOMA
As cutaneousmelanomas aremore common thanUM, the single-
cell technology is more established in cutaneous melanoma
research (Joshi et al., 2014; Tirosh et al., 2016; Gerber et al.,
2017). Indeed, researchers have already been able to identify
and profile malignant melanoma cell clones/subclones and CTC
transcriptomic signatures (Joshi et al., 2014; Tirosh et al., 2016;
Gerber et al., 2017).
ScRNA-seq remains the most common approach to
interrogate the molecular profiles of melanoma cells. A
comprehensive scRNA-seq analysis of the benign nevus cells
compared with melanoma malignant cells was used to elucidate
the molecular mechanisms of early melanoma development
(Kunz et al., 2018). Researchers have also combined pseudotime
and scRNA-seq analyses in short-term melanoma cultures
comprising cells at different stages of malignancy to detect
specific gene expression changes. The findings support that
a unique molecular signature underlies cutaneous melanoma
transformation; this signature might represent targets for
preventing disease progression (Loeffler-Wirth et al., 2018).
ScRNA-seq data have also been used to stratify melanoma cells
from patients with different melanoma subtypes. In addition,
scRNA-seq data have identified gene signatures for melanoma
subtype classification/stratification that might be useful for
improving cutaneous melanoma diagnosis and management
(Gerber et al., 2017).
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Treatment of metastatic melanomas was limited before the
advent of BRAF inhibitors and immunotherapy. Studies of
intratumor heterogeneity and the effects of such heterogeneity
on melanoma resistance spurred the development of the targeted
therapies and immunotherapeutics used today (Luke et al.,
2017). Improving our understanding of tumor heterogeneity
by performing genome-wide transcriptomics combined with
single-cell phenotyping and single-cell functional proteomics
will no doubt help us to understand the transition from drug-
sensitive to drug-resistance cells and to identify specific signaling
networks underlying melanoma drug-induced resistance (Su
et al., 2017). Single-cell transcriptomic data have helped us
identify several pathways associated with cellular adaptations to
BRAF inhibitors (Luke et al., 2017). In addition, Fluidigm C1 and
10× Genomics platforms are being used to identify rare drug-
resistant melanoma cellular populations; here, scRNA-seq And
Klustering Evaluation has helped us to understand the response
to BRAF inhibitor treatment and identify resistant signatures (Ho
et al., 2018).
Single-cell isolation in the context of metastatic melanoma has
also been used to study CTCs and identify antibodies to enrich for
melanoma CTCs (Ulmer et al., 2004; Karakousis et al., 2013) that
can be applied to UM. These studies have shown that a higher
melanoma CTC count in patients correlates with shorter survival
rates, metastatic tumors, and higher numbers of proliferating
cells (Ulmer et al., 2004; Karakousis et al., 2013; De Souza et al.,
2017).
CURRENT TRENDS IN SINGLE-CELL
TECHNOLOGY FOR UVEAL MELANOMA
The TME of UM comprises the melanoma cells, infiltrating
immune cells such as macrophages and lymphocytes, as well as
supporting stromal cells and blood vessels. Initiating mutations
in UM, such as GNA1 or GNA11, have been extensively studied
in UM. Other driver mutations include EIF1AX and SF3B1,
which are associated with good and intermediate prognoses,
respectively, whereas BAP1 mutations portend a poor prognosis
and the risk of metastatic disease (Ewens et al., 2014; Koopmans
et al., 2014; Decatur et al., 2016; Yavuzyigitoglu et al., 2017). The
loss of nuclear BAP1 expression is associated with monosomy
3, a key alteration in clinical prognostication in UM (Farquhar
et al., 2018; Smit et al., 2018; Coupland et al., 2020; Figueiredo
et al., 2020; Zhang et al., 2020). Another multicentered validated
prognostic test, the DecisionDx-UMTM is available in the USA
and Canada and uses GEP to distinguish Class 1 UM with a low
risk of metastasis and Class 2 UM with a high risk of metastasis
(Harbour, 2014).
Although attempts have been made to improve our molecular
understanding of the tumor microenvironment of UM by
the microdissection of these subpopulations of cells and the
application of NGS, these studies are still limited to the use of the
bulk cells approach (Karlsson et al., 2020; Krishna et al., 2020).
Recently, Karlson et al. provided the largest whole-genome
analysis of UM. In their study, they profiled mUM as well as
their tumor-infiltrating lymphocytes. Compatible with previous
publications (Ewens et al., 2014; Koopmans et al., 2014; Decatur
et al., 2016; Yavuzyigitoglu et al., 2017), they found that BAP1
mutations are key events in UM metastasis. However, they also
noted other mutations involving PBRM1 and EZH2 as well
as more novel mutations such as TET1, TET2, and ASXL2,
which are epigenetic regulators, which occur later in metastatic
development. They also detected deletions of CDKN2a that were
associated more with metastatic tumors rather than primary
UM. In profiling tumor-infiltrating lymphocytes, they found
expression of PD-1, Tim3, and LAG3, which are checkpoint
receptors. These findings were in agreement with data published
by Figueiredo et al. (2020).
Krishna et al. (2020) also focused on interrogating the
TME in mUM liver deposits. They performed NanoString-
based transcriptomic profiling of 40 mUM liver samples in
comparison with 6 control liver specimens. They confirmed their
preliminary data (Krishna et al., 2017; Figueiredo et al., 2020) by
demonstrating that the M2 macrophage actively contributed to
the immunosuppressive environment within the mUM and was
characterized by the upregulation ofAXNA1, CD74,CXCR4,MIF,
STAT3, PLA2G6, and TGFB1 in addition to previously described
genes, such as LGALS3 andHLA-DRA (Krishna et al., 2020). This
study also revealed several novel genes that were upregulated by
mUM, such as DUSP4, IRF4/MUM1, and CD44 (Krishna et al.,
2020).
As the single-cell approaches in UM are only just emerging,
the literature base is relatively sparse. Most studies have focused
predominantly on CTCs in UM (see in more detail later in 4.2)
(Tobal et al., 1993; Foss et al., 1995; Keilholz et al., 2004; Boldin
et al., 2005; Callejo et al., 2007; Schuster et al., 2007; Fernandes
et al., 2008; Ulmer et al., 2008; Pinzani et al., 2010; Suesskind et al.,
2011; Torres et al., 2011; Bidard et al., 2014; Mazzini et al., 2014;
Tura et al., 2014, 2016; Bande et al., 2015; Eide et al., 2015; Terai
et al., 2015; Alix-Panabières and Pantel, 2016; Anand et al., 2019;
Jin and Burnier, 2020).
Papers describing true single-cell approaches in UM are
limited, and these include a recent paper (Durante et al., 2020)
and a meeting abstract (Rodriguez et al., 2020).
Single-Cell Approaches to Interrogate the
Uveal Melanoma Microenvironment
Recently, Durante et al. (2020) have interrogated the UM TME
using the single-cell approach. In their study, 59,915 tumor- and
non-neoplastic single cells were isolated from eight primary and
three metastatic samples and analyzed by scRNA-seq on the 10×
Genomics platform. The gene expression data clustered similarly
with the Class 1 and Class 2 GEP clinical prognostic test for
UM. However, using single-cell resolution, of the 12 genes within
these tests, EIF1B, HTR2B, ECM1, CDH1, and ROBO1 genes were
found to be expressed predominantly in tumor cells, whereas
SATB1was expressed in predominantly T cells. The remaining six
genes were expressed by both tumor and immune cells.
Single-cell CNV analysis revealed new evidence that canonical
CNVs did not always occur as a single early event (as
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previously suggested) (Arozarena and Wellbrock, 2019). Rather,
it seems that UM cells continue to evolve alongside tumor
progression. Class 1 UMs were seen to contain loss of 1p,
3, and 8p, whereas Class 2 UMs were detected to have a
gain of 6p and 6q. In addition, five tumors’ initial gain of
8q followed by 8p were detected. On top of that, this result
confirmed the association between signature driver mutations
and canonical/non-canonical CNV subclones, which contribute
to tumor progression.
More importantly, this study showed that tumor-infiltrating
immune cells express the checkpoint marker LAG3 rather than
PD1 or CTLA4. LAG3 might, therefore, constitute a novel
candidate for immune checkpoint blockade in patients with
high-risk UM, who typically exhibit a poor response to PD1
and CTLA4 checkpoint inhibition (Jindal, 2018). This approach
(Durante et al., 2020) is an excellent example of how single-
cell analysis can provide a higher resolution of transcriptomic
changes in individual UM and tumor-infiltrating immune cells
and help validate findings from bulk cell approaches (Krishna
et al., 2017).
In a recent abstract publication by Rodriguez et al. (2020),
they identified the novel long non-coding RNA (lncRNA)
expression in UM and their association with BAP1 functionality.
One hundred and three UM samples were analyzed by RNA-
seq, which included quality control, trimming, alignment, and
transcript discovery. From this, 104 novel transcripts were
detected, of which 32 were differentially expressed between
Class 1 and Class 2 UMs (Rodriguez et al., 2020). Single-cell
RNA sequencing was then used to assess the tumor-specific
lncRNA expression in eight primary and threemUM samples and
revealed 10 lead lncRNAs to be expressed only in the tumor cells.
Although further work is required, this novel data reveals the
further potentials of single-cell approaches for the interrogation
of UM.
Single-Cell Approaches to Interrogate
Circulating Tumor Cells in Uveal Melanoma
For detecting CTCs, some of the previous melanoma CTCs
markers used include melanoma-associated chondroitin sulfate
proteoglycan (Ulmer et al., 2008; Suesskind et al., 2011; Eide et al.,
2015), melanoma cell adhesion molecule (CD146), NKI/beteb
and NKI/C3 (Tura et al., 2014), and high-molecular-weight
melanoma-associated antigen (MHW-MAA). Additionally,
combining two antibodies is more efficient in isolating UM
CTCs (Tura et al., 2014). However, CellSearch CTC studies,
the standardized CellSearch R© technique, consist of the first
immunomagnetically enriching CD146 melanoma cells and
subsequently staining the cell mixture with MHW-MAA.
Only cells with the MHW-MAA staining and lacking CD45
and CD34 staining for leukocytes and endothelial cells,
respectively, are counted as CTCs (Angi et al., 2013; Bidard
et al., 2014; Bande et al., 2015; Terai et al., 2015; Anand et al.,
2019).
Similar to cutaneous melanomas, data from most UM studies
have supported that the CTC count in UM correlates with the
extent of hepatic metastasis and thus survival (Keilholz et al.,
2004; Ulmer et al., 2008; Bidard et al., 2014; Mazzini et al.,
2014; Tura et al., 2016; Anand et al., 2019). However, data
from a few studies performed on CellSearch contradict this
and suggest no correlation with clinical parameters or tumor
burden in the liver (Bande et al., 2015; Terai et al., 2015).
Although the reason for this is unclear, it may be due to
the increased sensitivity of CellSearch in detecting CTCs. As
the clinical significance for CTCs remains unknown, single-cell
analyses on CTCs detected in patients with nevi (Bande et al.,
2015) and non-metastatic UM compared with CTCs present
in patients with metastasis might allow us to determine their
clinical significance.
One of the earliest CTC analyses in UM was conducted by
Angi et al. (2013). They used the CellSearch system to detect
CTCs in patients with high- and low-risk UM and showed
a strong correlation between CTC presence and monosomy
3. Bande et al. (2015) also evaluated the presence of CTCs
in benign choroidal nevus (premalignant), non-metastatic UM,
and a case of UM with high-risk features (i.e., extrascleral
extension and epithelioid histology). They found no CTCs in
the benign nevi but did identify CTCs in up to 50% non-
metastatic UM (<1 CTC per 7.5ml of blood). An even higher
number of CTCs were detected (3 CTCs per 7.5ml of blood)
in the case of high-risk UM. Anand et al. (2019) determined
the detection frequency of CTCs in the blood in a cohort of
40 patients with primary or mUM. They confirmed that CTCs
are more common in early-stage UM patients with adverse
prognostic factors (Class 2 GEP and monosomy 3) and that the
presence of CTCs predicts the risk of distant metastasis and poor
clinical outcomes.
Others have used real-time PCR to show that the expression
of biomarkers, including tyrosinase messenger RNA and
MelanA/MART1 in blood, correlates with the presence of CTCs
(Keilholz et al., 2004; Callejo et al., 2007; Schuster et al., 2007;
Pinzani et al., 2010). With single-cell isolation and analytic
techniques available, we can now determine both the single-cell
expression of these and other novel biomarkers and the levels of
expression that might be of metastatic relevance.
Tissue and liquid biopsy samples have been reported to show
differences inmolecular profiles inmost cancers (Neumann et al.,
2018). Intratumoral and/or spatial heterogeneity within a tumor
nodule is one of the causes of such differences. Although tissue
biopsies are still undertaken for diagnosis and prognostication,
it is recognized that they can be limited by intratumoral
heterogeneity and may not necessarily reflect the complex profile
within the entire tumor. Interestingly, primary UMs suffer less
from such intratumoral heterogeneity with respect to CNV
(Coupland et al., 2015), although there is limited information
addressing their mutational variation. Tumor biopsies may also
fail to reveal the secondary molecular driver mutations that drive
tumor transformation or metastasis. Liquid biopsies that include
the analysis of CTC, circulating tumor DNA, and circulating
microRNA have been shown to carry such information that
may allow us to understand the CTC genome as they progress
according to the disease status. Current studies for the detection
of CTCs seem inconsistent and focus on the number of CTCs,
whereas circulating tumor DNA has been shown to provide
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FIGURE 1 | Applications of Single-Cell Technology in Uveal Melanoma. (A) Potential applications of single-cell analysis in UM. In premalignant choroidal nevi:
Single-cell analysis can be used to study the mechanisms that underlie malignant transformation and identify biomarkers for early detection and even prevention. In
uveal melanomas: Single-cell analysis can be used to study the tumor microenvironment to determine how immune cells and stromal cells might contribute to
tumor-cell survival. Similar applications in treated and untreated melanoma cells or patient samples resistant to treatment might allow us to identify subclones of
malignant cells and subsequently develop personalized or targeted therapies for drug-resistant UM. In the blood: Studying the nature of CTCs will allow us to
determine which CTCs are likely to result in metastatic deposits. In the liver and other organs: Studying metastatic cells vs. primary UM cells might allow us to identify
biomarkers and the underlying mechanisms of metastatic disease, which will allow us to develop treatment interventions. Single-cell Workflow: Tumor
microenvironment is dissected using single-cell sorting tools. Subclone populations may then be identified and downstream analysis performed on each individual cell.
Currently, scRNA-seq is the most commonly used approach to interrogate the TME and has been used to confirm bulk cell gene expression analysis of Class 1 and
Class 2 UMs at a single cell level (Durante et al.). Other techniques that are being explored include scDNA-seq and scCNV analyses. (B) DEParray NXTTM analysis
demonstrating the detection of BAP1-negative and BAP1-positive cells with activated CD163 macrophages in a patient sample that showed high-risk histology
features of epithelioid histology and large basal diameter and height. The patient also had copy neutral-loss of heterozygosity on 3p21.31p21.2 and gain of 8q, losses
of 1p and 6q that are recognized as high-risk cytogenetic features. (C) DEParray NXTTM brightfield image demonstrating how single cells can be verified and debris
and duplets can be excluded for a higher quality of sampling. (D) Histology from patient sample UM14 that had high-risk cytogenetic features. Top panel, Left panel:
Hematoxylin and eosin stain showing the epithelioid cytology. Right panel: BAP1 immunohistochemistry staining shows no loss of BAP1 expression. Lower panel, Left
panel: Hematoxylin and eosin stain showing the epithelioid cytology. Right panel: BAP1 IHC staining show loss of BAP1 expression.
added insight with relatively good sensitivity and specificity using
ultrasensitive droplet polymerase chain reactions technology
(Jin and Burnier, 2020). However, this may change with the
application of scRNA and scDNA on CTCs, and this may
represent the future applications of single-cell technology in
liquid biopsies.
Potential Single-Cell Applications in Uveal
Melanoma
Based on the applications in cutaneous melanomas and other
cancers, we propose a customized single-cell workflow for
UM research (Figure 1A). First, single-cell genomic profiling
by scRNA-seq and/or scDNA-seq can be used to elucidate
the molecular events underlying the transformation of a
premalignant nevus to invasive UM with metastasis. In addition,
we can identify tumor heterogeneity and the temporal and
spatial evolution of tumor subclones to help predict resistant
cell populations. Combining single-cell isolation techniques with
scRNA-seq and scDNA-seq, circulating single melanoma cells
in the blood may be identified, profiled and compared with





As UM is a rare disease, fresh tissue specimens are not
readily available for research use; as such, many rely on
melanoma cell lines (Gerber et al., 2017). In Asia, where UM
has a particularly low incidence (0.3–0.4 per million per year
vs. 5–8 million per year in Western countries) (Kaliki and
Shields, 2017; Tan et al., 2020), FFPE archival UM tissues
are readily available. We previously established the DEPArray
NxT workflow for intraocular lymphoma single-cell isolation,
followed by clonality and genomic analyses (Tan et al., 2019).
Using this approach, we provide proof-of-concept that other
single-cell sorting techniques, other than 10× genomics (used
by Durante et al.), may also be utilized for dissecting the
UM microenvironment. Using a modified single-cell isolation
protocol for FFPE tissues, we isolated UM cells and infiltrating
immune cells by selecting specific cell populations by antibody
staining image analysis and visual selection using the DEPArray
Nxt system (Figures 1B,C). We compared the findings with
current clinical prognostic standards that included histology,
BAP1 immunohistochemistry, and Affymetrix Chromosomal
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MicroArray analysis to demonstrate that it is possible to detect
single cells with DEPArray Nxt with the immunophenotype
corresponding to the slide samples.
Using this DEPArray single-cell image-screening approach
(Figure 1C), it was possible to isolate and quantify single UM
cells with or without BAP1 nuclear expression and immune
cells, such as CD8T cells and CD163+ activated macrophages,
from archival UM FFPE samples (Figure 1B). We showed
(Figures 1B–D) that we were able to correlate the loss of
nuclear BAP1 expression (Figure 1D) in individual UM cells
from a patient who presented with a large posterior choroid
melanoma with epithelioid histology (Figure 1D) and advanced
TNM staging (Figure 1B). Single nucleotide polymorphism array
detected copy neutral loss of heterozygosity on 3p21.31p21.2 and
gain of 8q, losses of 1p and 6q (Figure 1B). Of note, copy neutral
loss of heterozygosity of chromosome 3 is superior to monosomy
3 in predictingmetastasis (Onken et al., 2004). The loss of nuclear
BAP1 (detected on our sample by immunohistochemistry) is
also associated with an immunosuppressive microenvironment
in UM patients (Figueiredo et al., 2020), which aligns with
the low level of activated CD163 macrophages and absence of
CD8T cells in the histology of this UM sample (Figure 1B). This
single-cell approach may be used to isolate specific cells from
the UM microenvironment for further downstream, single-cell
transcriptomic and genomic analyses.
Although the genomic quality of this single-cell approach has
not been validated, it is a proof-of-concept demonstration that
such microdissection can be performed in UM, especially when
there is a rare cell population that cannot be detected by routine
flow cytometry.
Despite the difficulties in performing scRNA-seq, scDNA-
seq, and scCNV analyses on FFPE tissues, due to nucleic acid
alterations after formalin fixation, recent studies have optimized
such protocols to allow single-cell transcriptomic (Foley et al.,
2019) and genomics (Martelotto et al., 2017) in FFPE specimens
to achieve results comparable with frozen or fresh samples
(Hedegaard et al., 2014).
DISCUSSION
Applying single-cell technology to UM has largely been
restricted to identifying CTCs and limited to making correlations
with clinical prognostic features. However, current single-cell
technologies allow for transcriptomic and genomic analyses to be
performed on isolated CTCs. By interrogating CTCs by scRNA-
seq, scDNA-seq, and sc-CNV at the early and metastatic stages
of UM and comparing the data with those derived from the
original UM clone and/or the hepatic metastatic clone, it may
be possible to elucidate the specific signature of malignant and
non-malignant CTCs. The increasing success in detecting CTCs
with the CellSearch platform suggests that early surveillance of
circulating melanoma cells may soon become a reality, especially
as CellSearch has already been Food and Drug Administration-
approved for clinical use in other cancers.
As mentioned, scRNA-seq analysis of the TME of UM has led
to the discovery that UM immune cells express LAG3 rather than
the traditional ligands used in immunotherapy. This finding,
together with the demonstration of fibrotic collagenous bands
surrounding mUM, explains why there is an immunosuppressive
environment within these tumor nodules and why current
immunotherapies are not successful in UM. Novel treatment
strategies are, therefore, urgently required. Further interrogation
of the TME in UM hepatic metastases and drug-resistant tumor
cells may reveal novel targets and biomarkers for such new
targeted therapies.
Small sample sizes greatly limit the study power in mUM
research. Moreover, single-cell tools are still not widely available
in all institutions and countries. International collaborations that
combine multicenter, single-cell research are thus crucial for the
development and validation of novel findings. Such international
collaborations might reveal genomic and transcriptomic
differences that underlie the differences in UM survival and
outcomes in different countries. Finally, forming an mUM
research consortium will likely help develop standardized
protocols that will ensure consistency in data production and a
high standard of single-cell research.
We propose that FFPE tissues can be used to overcome sample
size limitations and generate pilot data before sourcing fresh
tissues for validation. We have developed an FFPE single-cell
approach using the DEParray platform that seems representative
of the UM tumor microenvironment. Pitfalls associated with
FFPE NGS analyses can be minimized with image-based single-
cell isolation to review single cells before selection using
brightfield or fluorescence images to eliminate false staining by
debris or duplets and improve the quality of the isolated cells.
Together with new techniques that improve the quality of FFPE
RNA and DNA, this FFPE single-cell approach might constitute
an alternative to help advance UM research.
With these opportunities, we hope that the next decade of
UM research will see an increase in single-cell-related studies
that will lead to the development of clinically applicable tools for
metastatic surveillance and new therapies.
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